R&D News | pharmaphorum

News

BioMarin’s Voxzogo shows promise in hypochondroplasia

BioMarin’s Voxzogo has been shown to increase growth rates in children with hypochondroplasia, a genetic cause of very short stature, in a phase 2 trial.

News

TORL rakes in $158m for ADCs, and other bio financings

Our regular round-up of financings in the biotech sector features rounds for TORL BioTherapeutics, Nvelop Therapeutics, D3 Bio, and Century Therapeutics.

News

Novartis adds clinical-stage protein degrader from Arvinas

Novartis has accelerated its efforts to develop protein degrader therapies by licensing a prostate cancer candidate from Arvinas on the brink of starting phase 3 trials in

News

Vertex wagers $4.9bn on Alpine kidney disease therapy

In another departure from its core focus on genetic medicines, Vertex Pharma has agreed a $4.9 billion purchase of Alpine Immune Sciences, adding a mid-stage drug candidat

News

e-therapeutics' chief executive Ali Mortazavi

e-therapeutics is latest UK biotech to seek AIM de-listing

e-therapeutics has become the latest UK biotech to say it plans to delist from the Alternative Investment Market (AIM) in another blow to the reputation of the London Stoc

News

UK calls time-out on post-Brexit rules opposed by industry

It has been more than four years since the UK left the EU, but the government is still being forced to delay the introduction of border control rules that could have conse

BioMarin’s Voxzogo shows promise in hypochondroplasia

TORL rakes in $158m for ADCs, and other bio financings

Novartis adds clinical-stage protein degrader from Arvinas

Vertex wagers $4.9bn on Alpine kidney disease therapy

e-therapeutics is latest UK biotech to seek AIM de-listing

UK calls time-out on post-Brexit rules opposed by industry

Roche trial offers hope to patients with rare kidney disease

How to meet your physicians where they are online

News

Editor's Picks